Program
blinatumomab
Also written as “Blinatumomab”, “MEDI-538” and “Blinatumomab (MT103)”.
Its studies are mostly in Precursor Cell Lymphoblastic Leukemia-Lymphoma · Lymphoma, Large B-Cell, Diffuse · Neoplasm, Residual · Lymphoma, Non-Hodgkin · Lymphoma, B-Cell, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 256 open or running | phase 4since Jul 27, 2020 | Jan 10, 2006 | Nov 24, 2027phase 2 · NCT04521231 |
| AstraZeneca | 20 open or running | phase 2since May 8, 2008 | Sep 28, 2007 | none ahead |
| Imugene | 10 open or running | phase 1since Sep 14, 2023 | Sep 14, 2023 | none ahead |
| Novartis | 11 open or running | phase 2since Jan 13, 2026 | Jan 13, 2026 | Sep 19, 2033phase 2 · NCT07387926 |
Also a collaborator on its studies: BeOne Medicines, Merck and amgen-astellas-biopharma-k-k.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 16 studies since Jan 10, 2006.
- Sep 12, 2017Phase 2 study in High-risk Diffuse Large B-cell LymphomaAmgen · NCT03298412 · 10 enrolled · United States, Australia, Belgium and more
- Oct 23, 2017Phase 1 study in RecurrenceAmgen · NCT03340766 · 31 enrolled · United States, Australia, France and more
- Mar 12, 2018Phase 3 study in Precursor Cell Lymphoblastic Leukemia-LymphomaAmgen · NCT03476239 · 121 enrolled · China
- Jul 27, 2020Phase 4 study in LeukemiaAmgen · NCT04506086 · 10 enrolled · United States
- Aug 18, 2020Phase 2 study in RecurrenceAmgen · NCT04521231 · 181 enrolled · United States, Argentina, Australia and more
- Jul 30, 2021Phase 3 study in Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Amgen · NCT04994717 · 303 enrolled · United States, Australia, Austria and more
- Sep 14, 2023Imugene's first study: phase 1 study in Bites and StingsNew to ImugeneImugene · NCT06063317 · 25 enrolled · United States
- Sep 18, 2023Phase 2 study in RecurrenceAmgen · NCT06054113 · 18 enrolled · China
- Aug 22, 2024Phase 2 study in Lupus Erythematosus, SystemicAmgen · NCT06570798 · 220 planned · United States, Australia, Belgium and more
- Oct 17, 2024Phase 1 study in LeukemiaAmgen · NCT06649006 · 6 enrolled · Japan
- Aug 14, 2025Phase 2 study in RecurrenceAmgen · NCT07134088 · 104 enrolled · United States, Japan
- Oct 29, 2025Phase 3 study in Precursor Cell Lymphoblastic Leukemia-LymphomaAmgen · NCT07223190 · 560 planned
- Jan 13, 2026Novartis's first study: phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNew to NovartisNovartis · NCT07387926 · 50 planned · Australia, France, Israel and more
- Oct 5, 2026Primary completion moved from 2028-12-05 to 2031-03-06Date moved laterphase 2 · +27 months · NCT07134088
Ahead
- Nov 24, 2027Primary completion: phase 2 study in RecurrenceAmgen · NCT04521231
- Aug 6, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicAmgen · NCT06570798
- Sep 7, 2029Primary completion: phase 3 study in Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Amgen · NCT04994717
- Mar 6, 2031Primary completion: phase 2 study in RecurrenceAmgen · NCT07134088
TargetBeta
“T cell surface glycoprotein CD3 cross-linking agent; B-lymphocyte antigen CD19 cross-linking agent”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| YK012rule | excyte-biopharma-ltd | phase 2 | 5 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rule | cullinan-therapeutics-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rule | cytocares-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 | Novartis | phase 1 | 3 |
| ATG-201rule | antengene-biologics-limited | phase 1 | 1 |
| KT501rule | kali-therapeutics-inc | phase 1 | 1 |
| KT502rule | kali-therapeutics-inc | phase 1 | 1 |
Studies
All 29 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07387926Precursor Cell Lymphoblastic Leukemia-Lymphoma · Australia, France, Israel and more | 2 | Recruiting | Novartis | Sep 19, 2033 | 50 |
| NCT07223190Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | Not yet recruiting | Amgen | Dec 30, 2031 | 560 |
| NCT07134088Recurrence · United States, Japan | 2 | Active, not recruiting | Amgen | Mar 6, 2031 | 104 |
| NCT06649006Leukemia · Japan | 1 | Completed | Amgen | Jul 30, 2025 | 6 |
| NCT06570798Lupus Erythematosus, Systemic · United States, Australia, Belgium and more | 2 | Recruiting | Amgen | Aug 6, 2028 | 220 |
| NCT06054113Recurrence · China | 2 | Active, not recruiting | Amgen | Jan 6, 2026 | 18 |
| NCT06063317Bites and Stings · United States | 1 | Terminated | Imugene | Feb 2, 2026 | 25 |
| NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) · United States, Australia, Austria and more | 3 | Active, not recruiting | Amgen | Sep 7, 2029 | 303 |
| NCT04521231Recurrence · United States, Argentina, Australia and more | 2 | Active, not recruiting | Amgen | Nov 24, 2027 | 181 |
| NCT04506086Leukemia · United States | 4 | Terminated | Amgen | Jul 4, 2024 | 10 |
| NCT03476239Precursor Cell Lymphoblastic Leukemia-Lymphoma · China | 3 | Completed | Amgen | Aug 21, 2019 | 121 |
| NCT03340766Recurrence · United States, Australia, France and more | 1 | Completed | Amgen | Nov 6, 2020 | 31 |
| NCT03298412High-risk Diffuse Large B-cell Lymphoma · United States, Australia, Belgium and more | 2 | Terminated | Amgen | Sep 30, 2019 | 10 |
| NCT03023878High-risk Diffuse Large B-Cell Lymphoma · United States, Canada, France and more | 2 | Completed | Amgen | Apr 4, 2019 | 47 |
| NCT02961881Lymphoma, Non-Hodgkin · United States, Australia, France and more | 1 | Completed | Amgen | Sep 2, 2021 | 35 |
| NCT02910063Lymphoma, B-Cell · United States, Australia, Belgium and more | 3 | Completed | Amgen | Mar 12, 2020 | 41 |
| NCT02393859Precursor Cell Lymphoblastic Leukemia-Lymphoma · Argentina, Australia, Austria and more | 3 | Completed | Amgen | Jul 17, 2019 | 111 |
| NCT02412306Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia · Japan | 2 | Completed | Amgen | Feb 6, 2019 | 66 |
| NCT02013167Recurrence · United States, Australia, Austria and more | 3 | Terminated | Amgen | Dec 29, 2015 | 405 |
| NCT02000427Recurrence · United States, France, Germany and more | 2 | Completed | Amgen | May 20, 2015 | 45 |
| NCT01741792Lymphoma, Large B-Cell, Diffuse · Germany | 2 | Completed | Amgen | Jul 2014 | 25 |
| NCT01471782Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, Austria, Canada and more | 2 | Completed | Amgen | Aug 2014 | 93 |
| NCT01466179Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, France, Germany and more | 2 | Completed | Amgen | Oct 2013 | 225 |
| NCT01209286Precursor Cell Lymphoblastic Leukemia-Lymphoma · Germany | 2 | Completed | Amgen | Mar 2012 | 36 |
| NCT01207388Burkitt Lymphoma · Austria, Belgium, France and more | 2 | Completed | Amgen | Feb 2014 | 116 |
| NCT00676871Leukemia, Lymphocytic, Chronic, B-Cell | 2 | Withdrawn | AstraZeneca | Mar 2010 | 30 |
| NCT00560794Precursor Cell Lymphoblastic Leukemia-Lymphoma · Germany | 2 | Completed | Amgen | Sep 2009 | 21 |
| NCT00538096Lymphoma, B-Cell | 1 | Withdrawn | AstraZeneca | Mar 2010 | 18 |
| NCT00274742Lymphoma, Non-Hodgkin · Germany | 1 | Completed | Amgen | Aug 2011 | 76 |
How it is read
Names in the registry
- “Blinatumomab”, 25 entries
- “MEDI-538”, 10 entries
- “Blinatumomab (MT103)”, 2 entries
- “blinatumomab”, 1 entry
Conditions, from the studies’ own filings
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 13 studies
- Lymphoma, Large B-Cell, Diffuse, 4 studies
- Neoplasm, Residual, 2 studies
- Lymphoma, Non-Hodgkin, 2 studies
- Lymphoma, B-Cell, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.